Germany-based multinational pharmaceutical company Boehringer Ingelheim has launched a new mobile app and web page self-test as part of its efforts to raise awareness of Idiopathic pulmonary fibrosis (IPF), a chronic, progressive, severely debilitating, and ultimately lethal lung disease for which there are no FDA-approved treatment options in the U.S. Although…
The U.S. Food and Drug Administration (FDA) organized a workshop on pulmonary fibrosis, which took place on September 26th, in collaboration with the Coalition for Pulmonary Fibrosis (CPF), with the purpose of advocating for the disease throughout the country. Four of the eight panelists at the…
This month, Boehringer Ingelheim presented data concerning the use of nintedanib in patients with idiopathic pulmonary fibrosis (IPF) at the European Respiratory Society International Congress. Data covered two identical phase 3 trials: INPULSIS-1 and INPULSIS-2. “These results provide important insight on the effect of nintedanib across the patients studied…
FibroGen Inc. (FibroGen) recently presented complete data from a clinical study involving the experimental drug FG-3019 in patients with idiopathic pulmonary fibrosis (IPF.) A large group of patients treated with FG-3019 showed a decrease in lung fibrosis. The data was presented during the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF) held in…
cinemafestival / Shutterstock.com Being diagnosed with an incurable, progressively debilitating and life-threatening disease is difficult to cope with. It is even more difficult when the disease is idiopathic, or “of unknown cause.” Former Charmed star Rose McGowan lost her father to an idiopathic form…
New findings resulting from a research collaboration between miRagen Therapeutics Inc., a biopharmaceutical company developing innovative microRNA-based therapeutics, and Yale University scientists demonstrate that synthetic microRNA-29 Mimic promiR-29 reversed fibrosis in a mouse model of pulmonary fibrosis. These findings were published in the journal EMBO Molecular Medicine…
Inflammation has long been considered an integral element of the biological process that leads to deadly scarring in idiopathic pulmonary fibrosis, one of a broad category of lung diseases classified as Interstitial lung disease (ILD) that includes more than 130 disorders characterized by scarring (i.e. fibrosis) and/or inflammation…
Researchers at Brown University in Providence, Rhode Island and collaborating institutions report having achieved some progress in the battle against idiopathic pulmonary fibrosis (IPF), a devastating lung disease that afflicts millions of people worldwide. Two experimental drugs have recently showed promise in clinical trials, and now a study last…
Founded in 2000, the Pulmonary Fibrosis Foundation (PFF) is a nonprofit organization dedicated to supporting research on the treatment of pulmonary fibrosis (PF) and finding a cure for the disease, as well as assisting patients and their families. The organization engages with local and regional PF communities all over the…
The Pulmonary Fibrosis Foundation (PFF) recently submitted research data about more than 1,100 patients who suffer from pulmonary fibrosis (PF) to the U.S. Food and Drug Administration (FDA), in order to participate in the Patient-Focused Drug Development Meeting for Idiopathic Pulmonary Fibrosis. The meeting will take place on September…
Get regular updates to your inbox.
